The US Food and Drug Administration (FDA) has approved a new indication for Merck’s Gardasil human papillomavirus (HPV) vaccine.

The approval applies to the prevention of anal cancer caused by HPV types 16 and 18, and the prevention of anal intraepithelial neoplasia (AIN) caused by HPV types 6, 11, 16 and 18 in males and females aged 9-26 years old.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Gardasil has approved in the US for use in girls and young women aged 9-26 to prevent cervical, vulvar and vaginal cancers caused by HPV types 16 and 18, genital warts caused by HPV types 6 and 11, and precancerous or dysplastic lesions caused by HPV types 6, 11, 16 and 18.

In addition, Gardasil was approved in the US for use in boys and men aged 9-26 for the prevention of genital warts caused by HPV types 6 and 11.

Merck Research Laboratories executive director Richard M Haupt said that the company was pleased with the new indication for Gardasil.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.